Paradigm Asset Management’s Pacira BioSciences PCRX Stock Holding History

Paradigm Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3,900	Closed	-$207K	–	819
2016 Q1	$207K	Hold	3,900	–	–	0.04%	307
2015 Q4	$299K	Sell	3,900 -36,300	-90%	-$2.06M	0.05%	323
2015 Q3	$1.65M	Sell	40,200 -200	-0.5%	-$12.3K	0.22%	140
2015 Q2	$2.86M	Hold	40,400	–	–	0.32%	100
2015 Q1	$3.59M	Buy	40,400 +4,900	+14%	+$497K	0.4%	79
2014 Q4	$3.15M	Sell	35,500 -100	-0.3%	-$9.46K	0.41%	83
2014 Q3	$3.45M	Buy	+35,600	New	+$3.46M	0.48%	77

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paradigm Asset Management's PCRX Position: Q2 2016 in Review

Paradigm Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2016, closing a stake of 3,900 shares — an estimated $207K sold.

Paradigm Asset Management first reported a position in PCRX in Q3 2014 and held it in 7 quarters. The position peaked at $3.59M in Q1 2015. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

Paradigm Asset Management reported no remaining Pacira BioSciences position as of Q2 2016 after selling out during the quarter.
Paradigm Asset Management sold 3,900 Pacira BioSciences shares in Q2 2016, an estimated $207K.
Paradigm Asset Management first reported a position in Pacira BioSciences in Q3 2014 and held it in 7 quarters.
Paradigm Asset Management's Pacira BioSciences position peaked at $3.59M in Q1 2015.
183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on Paradigm Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.